A 57-Year-Old African American Man with Severe COVID-19 Pneumonia Who Responded to Supportive Photobiomodulation Therapy (PBMT): First Use of PBMT in COVID-19

15 August 2020: Articles

Unusual or unexpected effect of treatment

Scott A. Sigman ^A* , Soheila Mokmeli ^A , Monica Monici ^A , Mariana A. Vetrici ^B

DOI: 10.12659/AJCR.926779

Am J Case Rep 2020; 21:e926779

Table 2. Evaluation criteria before and after photobiomodulation therapy in a COVID-19 patient.

Parameters	Before treatment	After treatment	Normal range or evaluation criteria
PSI	Class V (142)	Class II (67)	Risk Class (Points): DispositionClass I (130): Inpatient
SMART-COP	5	2	0 points: Very low risk of needing IRVS1 point: Low risk (1 in 20) of needing IRVS2 points: Moderate risk (1 in 10) of needing IRVS3 points: High risk (1 in 6) of needing IRVS≥4 points: High risk (1 in 3) of needing IRVS; Consider ICU admission
Brescia-COVID	4	0	0 – monitor1 – add O and monitor2 – CXR, ABG, O therapy, monitor>2 – HFNC and reassess. If still >2, intubate.
CAP total	36.68	82.82	Calculated based on (CAP) score questionnaire: 75–100%
CAP respiratory	67.52	87.17	75–100%
CAP well-being	0.0	73.07	75–100%
RALE	8	5	Lungs score dependent on extent of involvement based on consolidation or ground-glass opacities for each lung, total score is the sum of the score of the lungs: 0 – no involvement; 1 – 75% of lung involved.
WBC	10.7	6.5	4.5–11
CRP	15.1	1.23	3 mg/mL
O Requirement	2–3 L/min	1 L/min	0 L/min
SpO	93–94%	100%	≥94%
PSI – Pneumonia Severity Index; SMART-COP – Systolic blood pressure, Multilobar infiltrates, Albumin, Respiratory rate, Tachycardia, Confusion, Oxygen, and pH; CAP – Community-Acquired Pneumonia; RALE – Radiographic Assessment of Lung Edema; SpO – Oxygen saturation; WBC – White Blood Cells; CRP – C-Reactive Protein; IRVS – Intensive Respiratory or Vasopressor Support; CXR – Chest x-ray; ABG – Arterial Blood Gas; HFNC – High-Flow Nasal Cannula.